Whereas no difference in PFS at any side was observed in the FOXFIRE Combined Analysis (HR: 0.90 [95% CI: 0.79-1.02] p= 0.108), the risk of first progression in the liver as per competing risk analysis remained significantly lower for patients receiving SIR-Spheres® Y-90 resin microspheres, as previously shown also in the SIRFLOX study.
Adapted from Wasan HS et al. Lancet Oncol 2017; 18: 1159-71
Wasan HS et al. Lancet Oncol 2017; 18: 1159-71.
You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.
Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.
Click 'Continue' to proceed to the third-party Web site.
You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.
Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes
no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.
The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region.
Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.
Click 'Continue' to proceed to the other Sirtex region Web site.
By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.
